Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,426,686
  • Shares Outstanding, K 100,401
  • Annual Sales, $ 0 K
  • Annual Income, $ -235,940 K
  • EBIT $ -271 M
  • EBITDA $ -271 M
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.31

Options Overview Details

View History
  • Implied Volatility 78.85% ( -19.75%)
  • Historical Volatility 69.86%
  • IV Percentile 63%
  • IV Rank 14.06%
  • IV High 317.51% on 12/18/23
  • IV Low 39.80% on 06/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 206
  • Volume Avg (30-Day) 173
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 7,257
  • Open Int (30-Day) 6,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.76
  • Number of Estimates 8
  • High Estimate -0.64
  • Low Estimate -0.90
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +30.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.66 +9.59%
on 11/01/24
35.90 -15.57%
on 10/16/24
-3.00 (-9.01%)
since 10/14/24
3-Month
23.55 +28.73%
on 09/03/24
47.45 -36.12%
on 08/20/24
-13.57 (-30.93%)
since 08/14/24
52-Week
9.76 +210.55%
on 11/16/23
47.45 -36.12%
on 08/20/24
+19.96 (+192.85%)
since 11/14/23

Most Recent Stories

More News
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

DYN : 30.31 (-11.19%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

DYN : 30.31 (-11.19%)
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

DYN : 30.31 (-11.19%)
2 Breakout Biotech Stocks With CEO Insider Buying

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

DYN : 30.31 (-11.19%)
RLMD : 3.16 (-1.56%)
Chart of the Day: Dyne Therapeutics - Deeply Discounted

The Chart of the Day belongs to the biotechnology company Dyne Therapeutics (DYN) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...

DYN : 30.31 (-11.19%)
Why Shares of Dyne Therapeutics Fell This Week

Insiders sold more than 15,000 shares of company stock on Tuesday.

DYN : 30.31 (-11.19%)
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...

DYN : 30.31 (-11.19%)
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...

DYN : 30.31 (-11.19%)
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical...

DYN : 30.31 (-11.19%)
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM,...

DYN : 30.31 (-11.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 36.17
2nd Resistance Point 34.78
1st Resistance Point 32.55
Last Price 30.31
1st Support Level 28.93
2nd Support Level 27.54
3rd Support Level 25.31

See More

52-Week High 47.45
Fibonacci 61.8% 33.05
Last Price 30.31
Fibonacci 50% 28.60
Fibonacci 38.2% 24.16
52-Week Low 9.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar